Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,808 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Ikeda T, et al. J Thromb Thrombolysis. 2019 Nov;48(4):653-660. doi: 10.1007/s11239-019-01934-6. J Thromb Thrombolysis. 2019. PMID: 31432451 Free PMC article. Clinical Trial.
Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iekushi K, Yamanaka S, Yamada T, Inuyama L; Rivaroxaban PostMarketing Surveillance Registry Investigators. Ogawa S, et al. Among authors: ikeda t. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2520-2526. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.006. Epub 2014 Sep 20. J Stroke Cerebrovasc Dis. 2014. PMID: 25245483
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H. Ikeda T, et al. Tohoku J Exp Med. 2016 Dec;240(4):259-268. doi: 10.1620/tjem.240.259. Tohoku J Exp Med. 2016. PMID: 27904005 Free article.
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Atarashi H, Inoue H. Shimokawa H, et al. Among authors: ikeda t. Int J Cardiol. 2018 May 1;258:126-132. doi: 10.1016/j.ijcard.2018.01.141. Epub 2018 Feb 3. Int J Cardiol. 2018. PMID: 29429636 Free article. Clinical Trial.
Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry.
Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Akishita M, Hasebe N, Kario K, Mizokami Y, Nagata K, Nakamura M, Terauchi Y, Yamamoto T, Teramukai S, Kimura T, Kaburagi J, Takita A. Inoue H, et al. Among authors: ikeda t. J Cardiol. 2018 Oct;72(4):300-306. doi: 10.1016/j.jjcc.2018.02.018. Epub 2018 Apr 3. J Cardiol. 2018. PMID: 29625717 Free article.
6,808 results